DOP062 Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
2017
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
7
Citations
NaN
KQI